Regeneron Pharmaceuticals' Veopoz Gets FDA Approval for Adults, Children
August 18 2023 - 1:42PM
Dow Jones News
By Denny Jacob
Regeneron Pharmaceuticals said the Food and Drug Administration
approved Veopoz to treat patients aged 1 year old and up who have
CHAPLE disease.
The biotechnology company said the approval of Veopoz addresses
pre-approval inspections issues related to the aflibercept 8 mg
biologics license application. FDA action on the application is
expected in the next few weeks, Regeneron said.
CHAPLE is a rare hereditary disease that can cause potentially
life-threatening gastrointestinal and cardiovascular symptoms.
Regeneron said Veopoz would be the first treatment for adults
and children with CHAPLE.
There are fewer than 10 patients with CHAPLE disease identified
in the U.S., Regeneron said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
August 18, 2023 14:27 ET (18:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2024 to May 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From May 2023 to May 2024
